Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Central Garden & Pet Co Class A
CENTA
$2.41B
| $8.53M | ﹤0.01% |
292,197
+183,363
| +168% | +$5.3M |
|
1802
Cameco
CCJ
$42.6B
| $8.5M | ﹤0.01% |
92,909
+35,602
| +62% | +$3.21M |
|
1803
Plexus
PLXS
$7.04B
| $8.49M | ﹤0.01% |
57,755
+5,399
| +10% | +$792K |
|
1804
Enovis
ENOV
$1.48B
| $8.48M | ﹤0.01% |
318,503
-382,692
| -55% | -$11.3M |
|
1805
PUT
Canadian Natural Resources
CNQ
$98.1B
| $8.46M | ﹤0.01% |
250,000
-500,000
| -67% | -$16.2M |
|
1806
International Bancshares
IBOC
$4.57B
| $8.46M | ﹤0.01% |
127,370
+1,201
| +1% | +$81.3K |
|
1807
Flywire
FLYW
$2.22B
| $8.46M | ﹤0.01% |
597,295
-73,285
| -11% | -$1M |
|
1808
Resideo Technologies
REZI
$3.1B
| $8.45M | ﹤0.01% |
240,570
-21,091
| -8% | -$780K |
|
1809
Lemonade
LMND
$4.1B
| $8.44M | ﹤0.01% |
118,510
+32,345
| +38% | +$2.17M |
|
1810
Matador Resources
MTDR
$6.39B
| $8.43M | ﹤0.01% |
198,586
-19,890
| -9% | -$835K |
|
1811
PUT
HubSpot
HUBS
$12B
| $8.43M | ﹤0.01% |
21,000
+9,800
| +88% | +$4.06M |
|
1812
Penumbra
PEN
$12.9B
| $8.43M | ﹤0.01% |
27,104
-9,372
| -26% | -$2.59M |
|
1813
State Street SPDR Bloomberg High Yield Bond ETF
JNK
$7.33B
| $8.42M | ﹤0.01% |
86,600
-6,700
| -7% | -$651K |
|
1814
CALL
Cytokinetics
CYTK
$10.2B
| $8.4M | ﹤0.01% |
132,200
-400
| -0.3% | -$24.9K |
|
1815
Kulicke & Soffa
KLIC
$5.01B
| $8.39M | ﹤0.01% |
184,173
+110,137
| +149% | +$4.65M |
|
1816
American Eagle Outfitters
AEO
$2.73B
| $8.38M | ﹤0.01% |
317,885
+19,156
| +6% | +$379K |
|
1817
Affiliated Managers Group
AMG
$9.7B
| $8.38M | ﹤0.01% |
29,061
-18,237
| -39% | -$4.71M |
|
1818
CALL
Lionsgate Studios
LION
$3.49B
| $8.37M | ﹤0.01% |
+916,900
| New | +$6.52M |
|
|
CPRX
1819
DELISTED
Catalyst Pharmaceutical
CPRX
| $8.36M | ﹤0.01% |
358,175
-14,717
| -4% | -$328K |
|
1820
IES Holdings
IESC
$14.9B
| $8.34M | ﹤0.01% |
21,446
+8,269
| +63% | +$3.32M |
|
|
YALA
1821
Yalla Group
YALA
$823M
| $8.33M | ﹤0.01% |
1,200,915
+383,511
| +47% | +$2.74M |
|
1822
Merit Medical Systems
MMSI
$5.4B
| $8.31M | ﹤0.01% |
94,250
-1,122
| -1% | -$95.5K |
|
1823
Ultragenyx Pharmaceutical
RARE
$2.6B
| $8.26M | ﹤0.01% |
359,148
-66,203
| -16% | -$2.18M |
|
1824
Bath & Body Works
BBWI
$3.76B
| $8.26M | ﹤0.01% |
411,148
-431,816
| -51% | -$9.53M |
|
|
BCPC
1825
Balchem Corp
BCPC
$5.65B
| $8.25M | ﹤0.01% |
53,812
-998
| -2% | -$152K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.